ERBB2 and cancer: As indicated, most studies encapsulated additional therapeutic agents such as anti-Her-2-antobodies or anti-EGFR-antibodies, capable of targeting overexpressing cancer cells while simultaneously holding intrinsic tumoricidal power [81,82].